Last reviewed · How we verify
Nabilone Oral Capsule
Nabilone is a synthetic cannabinoid that mimics THC by binding to cannabinoid receptors in the central nervous system to produce antiemetic and analgesic effects.
Nabilone is a synthetic cannabinoid that mimics THC by binding to cannabinoid receptors in the central nervous system to produce antiemetic and analgesic effects. Used for Chemotherapy-induced nausea and vomiting (CINV), Chronic pain, Multiple sclerosis-related spasticity.
At a glance
| Generic name | Nabilone Oral Capsule |
|---|---|
| Also known as | TEVA-nabilone, TEVA-Nabilone Placebo |
| Sponsor | Centre for Addiction and Mental Health |
| Drug class | Synthetic cannabinoid |
| Target | CB1 and CB2 cannabinoid receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology; Pain Management; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Nabilone acts as a partial agonist at CB1 and CB2 cannabinoid receptors, which are involved in regulating nausea, vomiting, and pain perception. By activating these receptors, it suppresses the vomiting center and modulates pain signaling pathways. It is structurally similar to delta-9-tetrahydrocannabinol (THC) but is a fully synthetic compound with more predictable pharmacokinetics.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Chronic pain
- Multiple sclerosis-related spasticity
Common side effects
- Dizziness
- Drowsiness
- Dry mouth
- Euphoria
- Ataxia
- Vertigo
- Concentration difficulty
Key clinical trials
- Investigating the Effects of Nabilone on Endocannabinoid Metabolism (PHASE4)
- Nabilone for Agitation in Frontotemporal Dementia (PHASE2)
- Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder (PHASE1, PHASE2)
- A Pilot Trial of Nabilone for the Treatment of Obesity (PHASE2)
- DIalysis Symptom COntrol-Pruritus Outcome Trial (PHASE3)
- Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients (NA)
- Nabilone for Non-motor Symptoms in Parkinson's Disease (PHASE2)
- Nabilone for Non-motor Symptoms in Parkinson's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nabilone Oral Capsule CI brief — competitive landscape report
- Nabilone Oral Capsule updates RSS · CI watch RSS
- Centre for Addiction and Mental Health portfolio CI